Birchview Capital »

Phoenix Biotech Acquisition Class A shares owned by Birchview Capital

Quarter-by-quarter ownership of Phoenix Biotech Acquisition Class A (CERO) shares owned by Birchview Capital from 13F filings

Historical chart of Birchview Capital investment in Phoenix Biotech Acquisition Class A

Tip: Access up to 7 years of quarterly data

All positions including Phoenix Biotech Acquisition Class A held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Phoenix Biotech Acquisition Class A by Birchview Capital

Quarter filed Position value Share count Share price at filing
2024-03-31 $40k 13k 3.07

More positions owned by Birchview Capital

Bristol Myers Squibb (BMY)
Neurocrine Biosciences (NBIX)
Biodesix (BDSX)
Aziyo Biologics (ELUT)
ACADIA Pharmaceuticals (ACAD)
Encana Corporation (OVV)
Prothena Corp SHS (PRTA)
Quidel Corporation
Silk Road Medical Inc Common (SILK)
Stoke Therapeutics (STOK)
Phreesia (PHR)
United Therapeutics Corporation (UTHR)
Masimo Corporation (MASI)
Foghorn Therapeutics (FHTX)
Harrow Health (HROW)

View all positions for Birchview Capital

Top funds holding Phoenix Biotech Acquisition Class A

Arch Venture Corp
Sc China Holding
Jane Street
Birchview Capital
Geode Capital Management
FNY Investment Advisers
Kestra Private Wealth Services
Pineridge Advisors
Jpmorgan Chase & Co

View all funds holding Phoenix Biotech Acquisition Class A